Jules Peter Jan Douwes

Dr. Jules Peter Jan Douwes

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
JDJules Peter Jan Douwes
Jules Peter Jan Douwes
EHErik F. Hensen
Erik F. Hensen
Jeroen C. JansenJeroen C. Jansen
Jeroen C. Jansen
HGHans Gelderblom
Hans Gelderblom
JSJosefine Schopman
Josefine Schopman
(1) Background: NF2-related schwannomatosis, characterized by the development of bilateral vestibular schwannomas, often necessitates varied treatment approaches. Bevacizumab, though widely utilized, demonstrates variable effectiveness on hearing and tumor growth. At the same time, (serious) adverse events have been frequently reported. (2) Methods: A single center retrospective study was conducted, on NF2-related schwannomatosis patients treated with bevacizumab from 2013 to 2023, with the aim to assess treatment-related and clinical outcomes. Outcomes of interest comprised hearing, radiologic response, symptoms, and adverse events. (3) Results: Seventeen patients received 7.5 mg/kg bevacizumab for 7.1 months. Following treatment, 40% of the patients experienced hearing improvement, 53%, stable hearing, and 7%, hearing loss. Vestibular schwannoma regression occurred in 31%, and 69% remained stable. Further symptomatic improvement was reported by 41%, stable symptoms by 47%, and worsened symptoms by 12%. Treatment discontinuation due to adverse events was observed in 29% of cases. Hypertension (82%) and fatigue (29%) were most frequently reported, with no occurrences of grade 4/5 toxicities. (4) Conclusion: Supporting previous studies, bevacizumab demonstrated positive effects on hearing, tumor control, and symptoms in NF2-related schwannomatosis, albeit with common adverse events. Therefore, careful consideration of an appropriate management strategy is warranted.

1 May 2024 in Stroke
Verified
Journal Article
Open access
PDF file
JSJasper R. Senff
Jasper R. Senff
SSSanjula D. Singh
Sanjula D. Singh
MPMarco Pasi
Marco Pasi
WJWilmar M.T. Jolink
Wilmar M.T. Jolink
MRMark A. Rodrigues
Mark A. Rodrigues
HBH. BART BROUWERS
H. BART BROUWERS
BACKGROUND: Spontaneous intracerebral hemorrhage (ICH) in the cerebellum has a poor short-term prognosis, whereas data on the long-term case fatality and recurrent vascular events are sparse. Herewith, we aimed to assess the long-term case fatality and recurrence rate of vascular events after a first cerebellar ICH. METHODS: In this international cohort study, we included patients from 10 hospitals (the United States and Europe from 1997 to 2017) aged ≥18 years with a first spontaneous cerebellar ICH who were discharged alive. Data on long-term case fatality and recurrence of vascular events (recurrent ICH [supratentoria or infratentorial], ischemic stroke, myocardial infarction, or major vascular surgery) were collected for survival analysis and absolute event rate calculation. RESULTS: We included 405 patients with cerebellar ICH (mean age [SD], 72 [13] years, 49% female). The median survival time was 67 months (interquartile range, 23–100 months), with a cumulative survival rate of 34% at 10-year follow-up (median follow-up time per center ranged: 15–80 months). In the 347 patients with data on vascular events 92 events occurred in 78 patients, after initial cerebellar ICH: 31 (8.9%) patients had a recurrent ICH (absolute event rate, 1.8 per 100 patient-years [95% CI, 1.2–2.6]), 39 (11%) had an ischemic stroke (absolute event rate, 2.3 [95% CI, 1.6–3.2]), 13 (3.7%) had a myocardial infarction (absolute event rate, 0.8 [95% CI, 0.4–1.3]), and 5 (1.4%) underwent major vascular surgery (absolute event rate, 0.3 [95% CI, 0.1–0.7]). The median time to a first vascular event during follow-up was 27 months (interquartile range, 8.7–50 months), with a cumulative hazard of 47% at 10 years. CONCLUSIONS: The long-term prognosis of patients who survive a first spontaneous cerebellar ICH is poor and comparable to that of patients who survive a first supratentorial ICH. Further identification of patients at high risk of vascular events following the initial cerebellar ICH is needed. Including patients with cerebellar ICH in randomized controlled trials on secondary prevention of patients with ICH is warranted.

24 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JDJules Peter Jan Douwes
Jules Peter Jan Douwes
RERonald van Eijk
Ronald van Eijk
SMSilvana Maas
Silvana Maas
Jeroen C. JansenJeroen C. Jansen
Jeroen C. Jansen
EAEmmelien Aten
Emmelien Aten
EHErik F. Hensen
Erik F. Hensen
Background: Unilateral (uVS) and bilateral vestibular schwannoma (bVS) are distinct disease types, yet share tumorigenic features. This study examined causative genetic alterations in three groups: patients with NF2-related schwannomatosis (NF2), young patients with uVS (≤30 years), and older patients with uVS (≥40 years). Methods: Lymphocyte and vestibular schwannoma DNA was genetically analyzed. Outcomes included gene involvement, pathogenicity classification, variant type, effect, and location, and loss of heterozygosity (LOH) of chromosome 22. Results: Among 93 patients, 17% had NF2, 39% were ≤30 years with uVS, and 44% were ≥40 years with uVS. In all patients with NF2 (100%), two or more hits were detected in the tumor DNA, whereas patients with uVS had a slightly lower detection rate (89–98%). NF2-related tumors had a higher frequency of nucleotide variants (76%), while LOH events were more common in uVS (64–69%). Variants were mostly identified in NF2, with nonsense variants over-represented in patients with NF2 (38%) and frameshift variants more prevalent in uVS (44–51%). Conclusions: Biallelic NF2 inactivation primarily drives vestibular schwannoma tumorigenesis. In patients with NF2, two pathogenic NF2 variants or one NF2 variant with LOH are common, whereas patients with uVS often exhibit one NF2 variant with LOH. Additionally, variant types differ between patient groups.

20 March 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
JDJules Peter Jan Douwes
Jules Peter Jan Douwes
KKKimberley S. Koetsier
Kimberley S. Koetsier
VDVictor S. van Dam
Victor S. van Dam
Scott PlotkinScott Plotkin
Scott Plotkin
FBFrederick G. Barker
Frederick G. Barker
HSHelen A. Shih
Helen A. Shih
(1) Background: This study aimed to evaluate the efficacy and treatment-related toxicity of proton radiotherapy (PRT) for vestibular schwannoma (VS) in patients with neurofibromatosis type 2-related schwannomatosis (NF2). (2) Methods: Consecutive NF2 patients treated with PRT for VS between 2004 and 2016 were retrospectively evaluated, focusing on tumor volume, facial and trigeminal nerve function, hearing, tinnitus, vestibular symptoms, and the need for salvage therapy after PRT. (3) Results: Eight patients were included (median age 36 years, 50% female). Median follow-up was 71 months. Five (63%) patients received fractionated PRT and three (38%) received PRT radiosurgery for VS. Six patients (75%) received prior VS surgery; three also received bevacizumab. Six patients (75%) did not require salvage therapy after PRT. Two patients (25%) with residual hearing lost it after PRT, and six had already lost ipsilateral hearing prior to PRT. Tumor and treatment-related morbidity could be evaluated in six patients. Following PRT, conditions that occurred or worsened were: facial paresis in five (83%), trigeminal hypoesthesia in two (33%), tinnitus in two (33%), and vestibular symptoms in four patients (67%). (4) Conclusion: After PRT for VS, the majority of the NF2 patients in the cohort did not require additional therapy. Tumor and/or treatment-related cranial nerve deficits were common. This is at least partly explained by the use of PRT as a salvage treatment after surgery or bevacizumab, in the majority of cases. There remains the further opportunity to elucidate the efficacy and toxicity of proton radiotherapy as a primary treatment.

1 March 2026 in European Stroke Journal
Verified
Journal Article
Open access
FWFloor N H Wilting
Floor N H Wilting
JDJules Peter Jan Douwes
Jules Peter Jan Douwes
APAjay Patel
Ajay Patel
FSFloris H B M Schreuder
Floris H B M Schreuder
RDRuben Dammers
Ruben Dammers
CKCatharina J M Klijn
Catharina J M Klijn
Introduction: Precise volumetric evaluation of intracerebral haemorrhage (ICH), intraventricular haemorrhage (IVH) and perihaematomal oedema (PHO) is essential but manual segmentation is time-consuming and susceptible to variability. We aimed to develop and externally validate a deep learning model for simultaneous segmentation of ICH, IVH and PHO on non-contrast CT (NCCT) in patients with spontaneous ICH. Patients and methods: A 3D U-net model was trained with 5-fold cross-validation on baseline NCCTs from 301 patients included in 2 prospective multicentre studies. External validation was performed on 141 baseline NCCTs from another multicentre study. Model performance was evaluated against manual ground truth segmentations using the Dice similarity coefficient (DSC), intraclass correlation coefficients (ICC) and Bland–Altman analyses. Results: The model achieved a median DSC of 0.93 (IQR 0.91–0.94) for ICH, 0.75 (IQR 0.57–0.82) for IVH and 0.53 (IQR 0.34–0.65) for PHO. Volume correlations were excellent for ICH (mean absolute and consistency ICC both 0.98 [95% CI 0.98–0.99]) and IVH (absolute ICC 0.97 [95% CI 0.92–0.98]; consistency ICC 0.98 [95% CI 0.96–0.99]), and moderate for PHO (absolute ICC 0.60 [95% CI -0.08–0.85]; consistency ICC 0.82 [95% CI 0.76–0.87]). Bland–Altman analyses demonstrated a bias for ICH of −0.48 mL (LoA −8.21 to 7.26), for IVH of −1.68 mL (LoA −7.35 to 3.99) and for PHO of 13.91 mL (LoA −4.85 to 32.68). Discussion and conclusion: The model enables accurate automated segmentation of ICH, while IVH and PHO segmentation remain more challenging. Automated segmentations may already serve as reliable pre-segmentations in research, but require visual assessment and correction, in particular for IVH and PHO.

8 April 2026 in BMJ Open
Verified
Journal Article
Open access
JDJules Peter Jan Douwes
Jules Peter Jan Douwes
ATAnnemijn L Tops
Annemijn L Tops
PDPetra Dibbets-Schneider
Petra Dibbets-Schneider
BVBerit M Verbist
Berit M Verbist
CBConstanza A Fuentealba Bassaletti
Constanza A Fuentealba Bassaletti
HGHans A Gelderblom
Hans A Gelderblom
Introduction: Treatment with bevacizumab achieves both tumour stabilisation or regression and preservation or improvement of hearing. However, the efficacy of bevacizumab varies between patients and within patients. Side effects due to bevacizumab treatment are also common. It would be of value to predict therapeutic response prior to initiating therapy to prevent unnecessary exposure in patients unlikely to benefit. Methods and analysis: We aim to recruit 25 patients with NF2 -related schwannomatosis (NF2) with bilateral vestibular schwannomas. Patients will receive an intravenous injection of 37 MBq [ 89 Zr]bevacizumab followed by positron emission tomography (PET)/CT imaging 4 days later. After clinical evaluation at baseline, patients undergo bevacizumab treatment and are followed up at 3 and 6 months. The primary objective is to examine associations between pretreatment [ 89 Zr]bevacizumab uptake on PET/CT and changes in multiple hearing outcomes and radiological characteristics of the target tumour following treatment. Secondary outcome measures include vestibular functioning, patient reported outcome measures, cranial nerve functionality, peripheral neurology, non-target schwannoma response and renal function. Given the explorative nature of the study, associations between PET-derived metrics and clinical and radiological outcomes will be examined without formal hypothesis testing, using generalised estimating equations to account for within-patient correlation. Pairwise associations will be summarised in an association matrix with multiplicity addressed using an all-resolutions inference approach, and findings will be considered hypothesis generating. Ethics and dissemination: This study was submitted via the Clinical Trials Information System reviewed and approved by the Medical Research Ethics Committee Leiden–The Hague–Delft Delft. The study findings will be disseminated through publication in peer-reviewed scientific journals and by presentation at national and international conferences. Trial registration number: The trial is registered at ClinicalTrials.gov Protocol Registration and Results System under the registration ID: NCT05685836 .